About 400,000 people in Europe live with Pulmonary Fibrosis and some 100,000 patients die each year from the disease. The most common type of PF is IPF (Idiopathic Pulmonary Fibrosis), accounting for 200,000 patients in Europe. EU-IPFF, the European Patient organization presently runs the “Breathing Life” campaign to raise awareness of the disease and encourages spread of the campaign. Oxcia is happy to share.
About 400,000 people in Europe live with Pulmonary Fibrosis and some 100,000 patients die each year from the disease. The most common type of PF is IPF (Idiopathic Pulmonary Fibrosis), accounting for 200,000 patients in Europe. EU-IPFF, the European Patient… Continue reading IPF awareness month
Sandra Ekstedt has joined Oxcia as Senior Scientist, a very welcome reinforcement as Sandra has a strong background in inflammation, immunology and airway disease with a PhD and over 10 years of work in the field. Sandra will primarily work… Continue reading Oxcia welcomes Senior Scientist Sandra Ekstedt
Oxcia is happy about all productive meetings and insightful discussions with pharma and investors at the LSX Nordic Congress. If you missed the congress and want to learn more about Oxcia and our exciting projects, please get in touch or… Continue reading LSX Nordic Congress
